リバーセル株式会社

What it does

"Rebirthel is a pioneering biotech company focused on the development and operationalization of cell-based cancer immunotherapies. Utilizing cutting-edge technology developed by Dr. Hiroshi Kawamoto, Director of the Institute for Frontier Medical Sciences at Kyoto University, Rebirthel aims to provide innovative treatments for immune-related diseases such as cancer and infections. The company specializes in producing killer T cells derived from pluripotent stem cells, offering a novel approach to immunotherapy. By focusing on the production of allogeneic T cells that can be administered to anyone, Rebirthel is revolutionizing the field of immunotherapy. With a vision to pioneer the era of treating diseases with T cell products, Rebirthel is at the forefront of the immunotherapy industry. Leveraging patented technology, the company is dedicated to providing advanced treatments using killer T cells regenerated from pluripotent stem cells, striving to offer cutting-edge therapies for patients in need."